145 related articles for article (PubMed ID: 38402895)
21. Cannabis for the treatment of Crohn's disease.
Kafil TS; Nguyen TM; MacDonald JK; Chande N
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012853. PubMed ID: 30407616
[TBL] [Abstract][Full Text] [Related]
22. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial.
Ponsioen CY; de Groof EJ; Eshuis EJ; Gardenbroek TJ; Bossuyt PMM; Hart A; Warusavitarne J; Buskens CJ; van Bodegraven AA; Brink MA; Consten ECJ; van Wagensveld BA; Rijk MCM; Crolla RMPH; Noomen CG; Houdijk APJ; Mallant RC; Boom M; Marsman WA; Stockmann HB; Mol B; de Groof AJ; Stokkers PC; D'Haens GR; Bemelman WA;
Lancet Gastroenterol Hepatol; 2017 Nov; 2(11):785-792. PubMed ID: 28838644
[TBL] [Abstract][Full Text] [Related]
23. Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial.
Sandborn WJ; Panés J; Danese S; Sharafali Z; Hassanali A; Jacob-Moffatt R; Eden C; Daperno M; Valentine JF; Laharie D; Baía C; Atreya R; Panaccione R; Rydzewska G; Aguilar H; Vermeire S;
Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):43-55. PubMed ID: 36240801
[TBL] [Abstract][Full Text] [Related]
24. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
D'Haens G; Baert F; van Assche G; Caenepeel P; Vergauwe P; Tuynman H; De Vos M; van Deventer S; Stitt L; Donner A; Vermeire S; Van De Mierop FJ; Coche JR; van der Woude J; Ochsenkühn T; van Bodegraven AA; Van Hootegem PP; Lambrecht GL; Mana F; Rutgeerts P; Feagan BG; Hommes D; ;
Lancet; 2008 Feb; 371(9613):660-667. PubMed ID: 18295023
[TBL] [Abstract][Full Text] [Related]
25. Visceral adiposity and inflammatory bowel disease.
Rowan CR; McManus J; Boland K; O'Toole A
Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
[TBL] [Abstract][Full Text] [Related]
26. Serum calprotectin as a biomarker for Crohn's disease.
Meuwis MA; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Piver E; Seidel L; Colombel JF; Louis E;
J Crohns Colitis; 2013 Dec; 7(12):e678-83. PubMed ID: 23845231
[TBL] [Abstract][Full Text] [Related]
27. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.
Kennedy NA; Heap GA; Green HD; Hamilton B; Bewshea C; Walker GJ; Thomas A; Nice R; Perry MH; Bouri S; Chanchlani N; Heerasing NM; Hendy P; Lin S; Gaya DR; Cummings JRF; Selinger CP; Lees CW; Hart AL; Parkes M; Sebastian S; Mansfield JC; Irving PM; Lindsay J; Russell RK; McDonald TJ; McGovern D; Goodhand JR; Ahmad T;
Lancet Gastroenterol Hepatol; 2019 May; 4(5):341-353. PubMed ID: 30824404
[TBL] [Abstract][Full Text] [Related]
28. Comparison of outcomes parameters for induction of remission in new onset pediatric Crohn's disease: evaluation of the porto IBD group "growth relapse and outcomes with therapy" (GROWTH CD) study.
Levine A; Turner D; Pfeffer Gik T; Amil Dias J; Veres G; Shaoul R; Staiano A; Escher J; Kolho KL; Paerregaard A; Martin de Carpi J; Veereman Wauters G; Koletzko S; Shevah O; Finnby L; Sladek M
Inflamm Bowel Dis; 2014 Feb; 20(2):278-85. PubMed ID: 24390062
[TBL] [Abstract][Full Text] [Related]
29. Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis.
Colombel JF; Reinisch W; Mantzaris GJ; Kornbluth A; Rutgeerts P; Tang KL; Oortwijn A; Bevelander GS; Cornillie FJ; Sandborn WJ
Aliment Pharmacol Ther; 2015 Apr; 41(8):734-46. PubMed ID: 25728587
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn's disease (ASTIClite): an open-label, multicentre, randomised controlled trial.
Lindsay JO; Hind D; Swaby L; Berntsson H; Bradburn M; Bannur C U; Byrne J; Clarke C; Desoysa L; Dickins B; Din S; Emsley R; Foulds GA; Gribben J; Hawkey C; Irving PM; Kazmi M; Lee E; Loban A; Lobo A; Mahida Y; Moran GW; Papaioannou D; Parkes M; Peniket A; Pockley AG; Satsangi J; Subramanian S; Travis S; Turton E; Uttenthal B; Rutella S; Snowden JA
Lancet Gastroenterol Hepatol; 2024 Apr; 9(4):333-345. PubMed ID: 38340759
[TBL] [Abstract][Full Text] [Related]
31. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial.
Stevens TW; Haasnoot ML; D'Haens GR; Buskens CJ; de Groof EJ; Eshuis EJ; Gardenbroek TJ; Mol B; Stokkers PCF; Bemelman WA; Ponsioen CY;
Lancet Gastroenterol Hepatol; 2020 Oct; 5(10):900-907. PubMed ID: 32619413
[TBL] [Abstract][Full Text] [Related]
32. [The clinical and endoscopic efficacy of step-up and top-down infliximab therapy in Crohn's disease].
Xiao YL; Chen BL; He Y; Gao X; Huang MJ; Hu PJ; Chen MH
Zhonghua Nei Ke Za Zhi; 2012 Feb; 51(2):100-3. PubMed ID: 22490808
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial.
Hanauer S; Liedert B; Balser S; Brockstedt E; Moschetti V; Schreiber S
Lancet Gastroenterol Hepatol; 2021 Oct; 6(10):816-825. PubMed ID: 34388360
[TBL] [Abstract][Full Text] [Related]
34. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
35. Top-down Infliximab Study in Kids with Crohn's disease (TISKids): an international multicentre randomised controlled trial.
Cozijnsen MA; van Pieterson M; Samsom JN; Escher JC; de Ridder L
BMJ Open Gastroenterol; 2016; 3(1):e000123. PubMed ID: 28090335
[TBL] [Abstract][Full Text] [Related]
36. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
Singh S; Murad MH; Fumery M; Sedano R; Jairath V; Panaccione R; Sandborn WJ; Ma C
Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1002-1014. PubMed ID: 34688373
[TBL] [Abstract][Full Text] [Related]
37. Low dose naltrexone for induction of remission in Crohn's disease.
Parker CE; Nguyen TM; Segal D; MacDonald JK; Chande N
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD010410. PubMed ID: 29607497
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study.
Smith PJ; Critchley L; Storey D; Gregg B; Stenson J; Kneebone A; Rimmer T; Burke S; Hussain S; Yi Teoh W; Vazeille S; Serna S; Steel A; Derbyshire E; Collins P; Dibb M; Flanagan P; Probert C; Verma AM; Subramanian S
J Crohns Colitis; 2022 Sep; 16(9):1436-1446. PubMed ID: 35390141
[TBL] [Abstract][Full Text] [Related]
39. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease.
Walters TD; Kim MO; Denson LA; Griffiths AM; Dubinsky M; Markowitz J; Baldassano R; Crandall W; Rosh J; Pfefferkorn M; Otley A; Heyman MB; LeLeiko N; Baker S; Guthery SL; Evans J; Ziring D; Kellermayer R; Stephens M; Mack D; Oliva-Hemker M; Patel AS; Kirschner B; Moulton D; Cohen S; Kim S; Liu C; Essers J; Kugathasan S; Hyams JS;
Gastroenterology; 2014 Feb; 146(2):383-91. PubMed ID: 24162032
[TBL] [Abstract][Full Text] [Related]
40. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR;
Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
